Avalon GloboCare (NASDAQ: ALBT) details pro forma effect of $9M RT9 sale

Rhea-AI Filing Summary

Avalon GloboCare Corp. filed an amended report providing unaudited pro forma financial information for the previously completed $9,000,000 sale of its subsidiary Avalon RT 9 Properties, LLC, which owned the company’s headquarters building in Freehold, New Jersey.

The pro forma balance sheet as of December 31, 2025 shows total assets decreasing from $23,400,737 historically to $16,106,352 after removing RT9-related assets and liabilities, while total equity increases from $9,230,108 to $11,178,393 mainly through a $1,948,285 adjustment to additional paid-in capital. For 2025, pro forma net loss attributable to common shareholders narrows from $18,098,503 to $17,356,400 by eliminating discontinued operations tied to the property business.

8-K Event Classification

Item 9.01 — Financial Statements and Exhibits

1 item

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Sale price of Avalon RT 9: $9,000,000 Total assets (historical vs pro forma 2025): $23,400,737 to $16,106,352 Total equity (historical vs pro forma 2025): $9,230,108 to $11,178,393 +5 more

8 metrics

Sale price of Avalon RT 9 $9,000,000 Consideration for 100% membership interests in Avalon RT 9

Total assets (historical vs pro forma 2025) $23,400,737 to $16,106,352 As of December 31, 2025 after RT9 sale adjustments

Total equity (historical vs pro forma 2025) $9,230,108 to $11,178,393 As of December 31, 2025 including $1,948,285 APIC adjustment

2025 net loss attributable to shareholders $18,098,503 to $17,356,400 Historical vs pro forma after removing discontinued operations

2024 net loss attributable to shareholders $7,903,394 to $7,039,604 Historical vs pro forma eliminating RT9 rental results

2025 basic and diluted EPS (continuing) $(5.41) Per share loss from continuing operations, unchanged pro forma

2024 basic and diluted EPS $(8.44) to $(7.52) Historical vs pro forma after RT9-related adjustments

Current liabilities (historical vs pro forma 2025) $14,147,114 to $4,927,959 As of December 31, 2025 after removing RT9-related items

Key Terms

Amended and Restated Membership Interest Purchase Agreement, unaudited pro forma consolidated financial information, discontinued operations, equity method investment, +1 more

5 terms

Amended and Restated Membership Interest Purchase Agreement regulatory

"entered into an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”)"

unaudited pro forma consolidated financial information financial

"to provide the unaudited pro forma consolidated financial information required by Item 9.01(b)"

discontinued operations financial

"Current assets of discontinued operations"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

equity method investment financial

"Income from equity method investment - Lab Services MSO"

An equity method investment is an accounting way to report ownership in another company when an investor has significant influence (commonly around 20–50% of voting rights). Instead of listing the other company’s full assets and debts, the investor records its share of that company’s profits or losses on its own income statement—like keeping track of your share of a neighborhood bakery’s monthly earnings. Investors care because those shared profits, losses and changes in the investee’s value directly affect the investor’s reported earnings and balance sheet, so this method can materially change a company’s financial picture and valuation.

derivative liability financial

"Change in fair value of derivative liability"

A derivative liability is an obligation a company owes because of a derivatives contract—such as an option, future, swap, or forward—that has moved against it and now has negative value. Think of it like a settled bet that turned into a bill: if market moves go the other way, the company may have to pay cash or deliver assets. Investors care because these liabilities can create sudden losses, add leverage or counterparty risk, and change a company’s true financial exposure beyond its everyday operations.

Understanding 8-K Material Events →

true 0001630212 0001630212 2026-02-18 2026-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 18, 2026

AVALON GLOBOCARE CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-38728		47-1685128
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification Number)

4400 Route 9 South, Suite 3100, Freehold, NJ 07728

(Address of principal executive offices, including zip code)

(732) 780-4400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALBT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Explanatory Note:

On February 18, 2026, Avalon Globocare Corp. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) reporting the Company and Wenzhao Lu (the “Purchaser”) entered into an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”), pursuant to which the Company sold to the Purchaser 100% of the membership interests of Avalon RT 9 Properties, LLC, a wholly owned subsidiary of the Company (“Avalon RT9”). Avalon RT9 was the owner of real property located at 4400 Route 9 South, Freehold, New Jersey 07728 , where the Company maintains its principal office space. The Original Report indicated that pro forma financial information required by Item 9.01(b) of Form 8-K would be filed by amendment.

This Current Report on Form 8-K/A amends the Original Report to provide the unaudited pro forma consolidated financial information required by Item 9.01(b) of Form 8-K. Except as described herein, this Form 8-K/A does not amend, modify, or update any other information contained in the Original Report.

-1-

Item 9.01. Financial Statements and Exhibits.

(b) Pro forma financial information*.

The unaudited pro forma consolidated financial information of the Company giving effect to the Amended MIPA consisting of

(i) the unaudited pro forma consolidated balance sheet as of December 31, 2025, and

(ii) the unaudited pro forma consolidated statements of operations and comprehensive loss of the Company for the years ended December 31, 2025 and 2024.

*Filed as Exhibit 99.1

(d) Exhibits.

Exhibit No.		Exhibit
99.1		Unaudited pro forma consolidated financial information
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AVALON GLOBOCARE CORP.
Dated: April 21, 2026	By:	/s/ Luisa Ingargiola
	Name:	Luisa Ingargiola
	Title:	Chief Financial Officer

-3-

Exhibit 99.1

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

The following unaudited pro forma consolidated balance sheet and statements of operations and comprehensive loss are based upon the historical consolidated financial statements of Avalon GloboCare Corp. (the “Company”). The unaudited pro forma consolidated financial information has been prepared to illustrate the effect of the sale (the “Sale”) of Avalon RT 9 Properties, LLC, a wholly owned subsidiary of the Company (“Avalon RT 9”). For a detailed description of the Sale, please see Note [1] of the accompanying unaudited pro forma consolidated financial information.

The unaudited pro forma consolidated balance sheet as of December 31, 2025 has been prepared by including the audited historical consolidated balance sheet of the Company as of December 31, 2025, adjusted to reflect the pro forma effect as if the Sale had been consummated on that date. The unaudited pro forma consolidated statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024 have been prepared by including the Company’s historical consolidated statements of operations and comprehensive loss, adjusted to reflect the pro forma effect as if the Sale had been consummated on January 1, 2024.

The historical consolidated financial statements referred to above for the Company were included in its Annual Reports on Form 10-K for the years ended December 31, 2025 and 2024, previously filed with the Securities and Exchange Commission (the “SEC”). The accompanying unaudited pro forma consolidated financial information and the historical consolidated financial information presented herein should be read in conjunction with the historical consolidated financial statements and notes thereto of the Company.

The unaudited pro forma consolidated balance sheet and statements of operations and comprehensive loss include pro forma adjustments which reflect transactions and events that (a) are directly attributable to the Sale, (b) are factually supportable, and (c) with respect to the statements of operations, have a continuing impact on consolidated results of operations. The pro forma adjustments are described in the accompanying notes to the unaudited pro forma consolidated financial information.

The unaudited pro forma consolidated financial information was prepared for informational purposes only and is not necessarily indicative of the financial position or results of operations that would have occurred if the Sale had been completed on the dates indicated, nor is it indicative of the future financial position or results of operations of the Company. Assumptions and estimates underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with the unaudited pro forma consolidated financial information. The accounting for the Sale is dependent upon final balances related to the assets and liabilities at the closing date that have yet to progress to a stage where there is sufficient information for a definitive measurement. Due to the fact that the unaudited pro forma consolidated financial information has been prepared based upon preliminary estimates and account balances other than those on the actual Sale closing date, the final amounts recorded for the Sale may differ materially from the pro forma consolidated financial information presented.

The unaudited pro forma consolidated financial information does not reflect future events that may occur after the Sale, including potential restructuring and related general and administrative cost savings. The pro forma adjustments are subject to change and are based upon currently available information.

AVALON GLOBOCARE CORP. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET

As of December 31, 2025

						Pro Forma
		Historical				Adjustments						Pro Forma
ASSETS
CURRENT ASSETS:
Cash		$	109,091			$	-					$	109,091
Receivable from sale of equity method investment			748,000				-						748,000
Prepaid expense and other current assets			282,170				-						282,170
Current assets of discontinued operations			356,616				(356,616	)		b			-
Total Current Assets			1,495,877				(356,616	)					1,139,261
NON-CURRENT ASSETS:
Property and equipment, net			727				-						727
Intangible assets, net			2,158,167				-						2,158,167
Goodwill			12,808,197				-						12,808,197
Non-current assets of discontinued operations			6,937,769				(6,937,769	)		b			-
Total Non-current Assets			21,904,860				(6,937,769	)					14,967,091
Total Assets		$	23,400,737			$	(7,294,385	)				$	16,106,352
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accrued professional fees		$	1,832,606			$	-					$	1,832,606
Accrued research and development fees			153,772				-						153,772
Accrued payroll liability and compensation			1,072,553				-						1,072,553
Accrued litigation settlement			363,450				-						363,450
Accrued liabilities and other payables			281,063				-						281,063
Accrued liabilities and other payables - related parties			100,000				-						100,000
Operating lease obligation			6,000				-						6,000
Advance from pending sale of noncontrolling interest - related party			3,158,078				(3,158,078	)		a			-
Derivative liability			34,156				-						34,156
Stock subscription liability			150,000				-						150,000
Bridge loan payable, net			197,341				-						197,341
Convertible note payable, net			737,018				-						737,018
Current liabilities of discontinued operations			6,061,077				(6,061,077	)		b			-
Total Current Liabilities			14,147,114				(9,219,155	)					4,927,959
NON-CURRENT LIABILITIES:
Non-current liabilities of discontinued operations			23,515				(23,515	)		b			-
Total Non-current Liabilities			23,515				(23,515	)		b			-
Total Liabilities			14,170,629				(9,242,670	)					4,927,959
EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized;
Series C Convertible Preferred Stock, 3,800 shares issued and outstanding at December 31, 2025; Liquidation preference $3.8 million at December 31, 2025			3,790,000				-						3,790,000
Series D Convertible Preferred Stock, 5,000 shares issued and outstanding at December 31, 2025; Liquidation preference $5 million at December 31, 2025			8,837,527				-						8,837,527
Series E Convertible Preferred Stock, 19,500 shares issued and outstanding at December 31, 2025; Liquidation preference $19.5 million at December 31, 2025			14,916,753				-						14,916,753
Common stock, $0.0001 par value; 100,000,000 shares authorized;4,857,476 shares issued and 4,854,009 shares outstanding at December 31, 2025			486				-						486
Additional paid-in capital			88,376,767				1,948,285			c			90,325,052
Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2025			(522,500	)			-						(522,500	)
Accumulated deficit			(105,934,101	)			-						(105,934,101	)
Statutory reserve			6,578				-						6,578
Accumulated other comprehensive loss			(241,402	)			-						(241,402	)
Total Avalon GloboCare Corp. stockholders' equity			9,230,108				1,948,285						11,178,393
Noncontrolling interest			-				-						-
Total Equity			9,230,108				1,948,285						11,178,393
Total Liabilities and Equity		$	23,400,737			$	(7,294,385	)				$	16,106,352

See notes to unaudited pro forma consolidated financial information.

2

AVALON GLOBOCARE CORP. AND SUBSIDIARIES

UNAUDITED PRO FROMA CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

For the Year Ended December 31, 2025

						Pro Forma
		Historical				Adjustments						Pro Forma
INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO		$	392,677			$	-					$	392,677
OTHER OPERATING EXPENSES:
Advertising and marketing expenses			843,497				-						843,497
Professional fees			5,254,207				-						5,254,207
Compensation and related benefits			1,101,574				-						1,101,574
Other general and administrative expenses			784,758				-						784,758
Total Other Operating Expenses			7,984,036				-						7,984,036
LOSS FROM OPERATIONS			(7,591,359	)			-						(7,591,359	)
OTHER (EXPENSE) INCOME
Interest expense - amortization of debt discount and debt issuance costs			(1,136,412	)			-						(1,136,412	)
Interest expense - other			(320,282	)			-						(320,282	)
Change in fair value of derivative liability			538,213				-						538,213
Loss on extinguishment of debt			(9,076,587	)			-						(9,076,587	)
Other income			67,554				-						67,554
Total Other Expense, net			(9,927,514	)			-						(9,927,514	)
LOSS BEFORE INCOME TAXES			(17,518,873	)			-						(17,518,873	)
INCOME TAXES			-				-						-
NET LOSS FROM CONTINUING OPERATIONS			(17,518,873	)			-						(17,518,873	)
NET LOSS FROM DISCONTINUED OPERATIONS			(742,103	)			742,103			d			-
NET LOSS		$	(18,260,976	)		$	742,103					$	(17,518,873	)
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST			-				-						-
NET LOSS AFTER NONCONTROLLING INTEREST			(18,260,976	)			742,103						(17,518,873	)
DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS			162,473				-						162,473
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS		$	(18,098,503	)		$	742,103					$	(17,356,400	)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:
Basic and diluted, continuing operations		$	(5.41	)		$	-					$	(5.41	)
Basic and diluted, discontinued operations			(0.23	)			0.23						-
Basic and diluted		$	(5.64	)		$	0.23					$	(5.41	)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted			3,210,779				3,210,779						3,210,779
COMPREHENSIVE LOSS:
NET LOSS		$	(18,260,976	)		$	742,103					$	(17,518,873	)
OTHER COMPREHENSIVE LOSS FROM CONTINUED OPERATIONS
Unrealized foreign currency translation loss			(9,402	)			(9,402	)					(9,402	)
COMPREHENSIVE LOSS			(18,270,378	)			732,701						(17,528,275	)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST			-				-						-
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS		$	(18,270,378	)		$	732,701					$	(17,528,275	)

See notes to unaudited pro forma consolidated financial information.

3

AVALON GLOBOCARE CORP. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

For the Year Ended December 31, 2024

						Pro Forma
		Historical				Adjustments						Pro Forma
REAL PROPERTY RENTAL REVENUE		$	1,333,403			$	(1,333,403	)		e		$	-
REAL PROPERTY OPERATING EXPENSES			1,065,574				(1,065,574	)		e			-
REAL PROPERTY OPERATING INCOME			267,829				(267,829	)					-
LOSS FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO			(846,588	)			-						(846,588	)
OTHER OPERATING EXPENSES:
Advertising and marketing expenses			237,671				-						237,671
Professional fees			1,822,105				(231,837	)		e			1,590,268
Compensation and related benefits			1,431,328				(122,474	)		e			1,308,854
Other general and administrative expenses			857,869				-						857,869
Total Other Operating Expenses			4,348,973				(354,311	)					3,994,662
LOSS FROM OPERATIONS			(4,927,732	)			86,482						(4,841,250	)
OTHER (EXPENSE) INCOME
Interest expense - amortization of debt discount and debt issuance costs			(1,411,042	)			119,228			e			(1,291,814	)
Interest expense - other			(983,486	)			658,000			e			(325,486	)
Interest expense - related party			(42,445	)			-						(42,445	)
Debt modification charge			(838,794	)			-						(838,794	)
Change in fair value of derivative liability			374,365				-						374,365
Other expense			(74,260	)			80			e			(74,180	)
Total Other Expense, net			(2,975,662	)			777,308						(2,198,354	)
LOSS BEFORE INCOME TAXES			(7,903,394	)			863,790						(7,039,604	)
INCOME TAXES			-				-						-
NET LOSS		$	(7,903,394	)		$	863,790					$	(7,039,604	)
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST			-				-						-
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS		$	(7,903,394	)		$	863,790					$	(7,039,604	)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:
Basic and diluted		$	(8.44	)		$	0.92					$	(7.52	)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted			936,614				936,614						936,614
COMPREHENSIVE LOSS:
NET LOSS		$	(7,903,394	)		$	863,790					$	(7,039,604	)
OTHER COMPREHENSIVE LOSS
Unrealized foreign currency translation loss			(273	)			-						(273	)
COMPREHENSIVE LOSS			(7,903,667	)			863,790						(7,039,877	)
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST			-				-						-
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS		$	(7,903,667	)		$	863,790					$	(7,039,877	)

See notes to unaudited pro forma consolidated financial information.

4

[1] Description of Sale

On February 18, 2026, the Company and Wenzhao Lu (the “Purchaser”), the Chairman of the Company’s Board of Directors, entered into an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”), pursuant to which the Company sold to the Purchaser 100% of the membership interests of Avalon RT 9 Properties, LLC, a wholly owned subsidiary of the Company (“Avalon RT 9”), for $9,000,000.

[2] Basis of Presentation

The unaudited pro forma consolidated financial information is prepared pursuant to Article 11 of Regulation S-X. The unaudited pro forma consolidated balance sheet and statements of operations and comprehensive loss are based upon the historical consolidated financial statements of the Company, which were included in its Annual Reports on Form 10-K for the fiscal years ended December 31, 2025 and 2024, previously filed with the SEC. The unaudited pro forma consolidated balance sheet as of December 31, 2025 has been prepared by including the audited historical consolidated balance sheet of the Company as of December 31, 2025, adjusted to reflect the pro forma effect as if the Sale had been consummated on that date. The unaudited pro forma consolidated statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024 have been prepared by including the Company’s historical consolidated statements of operations and comprehensive loss, adjusted to reflect the pro forma effect as if the Sale had been consummated on January 1, 2024.

[3] Pro Forma Adjustments

The following pro forma adjustments are included in the unaudited pro forma consolidated balance sheet and/or the unaudited pro forma consolidated statements of operations and comprehensive loss:

a. Reflects the elimination of advance received from the Purchaser of approximately $3 million.

b. Reflects the elimination of Avalon RT 9’s assets and liabilities.

c. Reflects the effect on additional paid-in capital related to the estimated gain on sale of Avalon RT 9 to Mr. Lu, the Company’s chairman of the Board of Directors. The Company recorded proceeds in excess of its carrying value (approximately $2 million) to additional paid-in capital as a result of the capital transaction with related party under applicable SEC regulations.

d. Reflects the elimination of the historical net loss from discontinued operations attributable to the sale of Avalon RT 9.

e. Reflects the elimination of the historical real property rental revenue, real property operating expenses, other operating expenses, and other expense attributable to the sale of Avalon RT 9.

5

FAQ

What transaction does Avalon GloboCare (ALBT) reflect in this 8-K/A?

Avalon GloboCare’s 8-K/A reflects the completed sale of 100% of Avalon RT 9 Properties, LLC for $9,000,000. This subsidiary owned the Freehold, New Jersey property that housed the company’s principal office space, and the buyer was director Wenzhao Lu.

How did the Avalon RT 9 sale affect ALBT’s pro forma balance sheet?

On a pro forma basis at December 31, 2025, total assets fall from $23,400,737 to $16,106,352 after removing RT9 assets. Total liabilities drop from $14,170,629 to $4,927,959, and total equity rises to $11,178,393 mainly via added paid-in capital.

How does the pro forma data change Avalon GloboCare’s 2025 net loss?

For 2025, historical net loss attributable to Avalon GloboCare common shareholders was $18,098,503. Pro forma adjustments remove discontinued operations related to RT9, reducing this to $17,356,400, while basic and diluted loss per share from continuing operations remains at $5.41.

What is shown for Avalon GloboCare’s 2024 results on a pro forma basis?

For 2024, real property rental revenue of $1,333,403 and related operating expenses of $1,065,574 are eliminated. Historical net loss of $7,903,394 improves to a pro forma net loss of $7,039,604, and basic and diluted loss per share improves from $8.44 to $7.52.

What discontinued operations adjustments are made in ALBT’s 2025 pro forma statement?

The 2025 pro forma statement removes net loss from discontinued operations of $742,103, linked to the RT9 property business. This adjustment takes total net loss from $18,260,976 historically to $17,518,873 and aligns earnings per share with continuing operations only.

How did the sale influence Avalon GloboCare’s liabilities?

Pro forma current liabilities decline sharply by removing items tied to discontinued operations and an advance from a pending noncontrolling interest sale. Total liabilities move from $14,170,629 historically to $4,927,959 on a pro forma basis at December 31, 2025.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION 148.0 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB